Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. on August 30, 2016. The filing addresses an "At Market" Issuance Sales Agreement entered into on June 23, 2016, with FBR Capital Markets & Co. The report provides an update on shares sold under this agreement and the filing of a legal opinion regarding the legality of the shares.
Key Financial Metrics
- Shares Sold: 766,149 shares of common stock sold to date under the Sales Agreement.
- Net Proceeds: Approximately $3.9 million received from the shares sold.
- Proposed Offering: The Company intends to file a prospectus supplement to issue and sell shares with an aggregate offering price of up to $4.0 million.
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide a clear value for these specific financial metrics.
Material Changes
The primary material event is the execution of the Sales Agreement allowing for the sale of common stock via an "at-the-market" offering. Since the initial agreement on June 23, 2016, the Company has successfully sold 766,149 shares. The filing also notes the submission of a legal opinion from counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., to support the registration statement.
Guidance, Outlook, and Risks
- Outlook: The Company plans to seek approval to sell up to an additional $4.0 million worth of shares through FBR.
- Risks and Contingencies: The Company is not obligated to make any sales under the agreement. There is no assurance that any shares will be sold, nor is there assurance regarding the price, amount, or timing of any future sales.
- Termination: The Sales Agreement will terminate upon the sale of all subject stock or earlier if terminated by the Company or FBR.
Investor Verification Checklist
- Verify the final net proceeds received from the 766,149 shares sold.
- Confirm the status of the additional prospectus supplement for the proposed $4.0 million offering.
- Review the legal opinion filed as Exhibit 5.1 regarding the legality of the shares.
- Monitor future filings for actual sales volumes and pricing under the Sales Agreement.